TY - JOUR AU - Tap, William D AU - Wagner, Andrew J AU - Schöffski, Patrick AU - Martin-Broto, Javier AU - Krarup-Hansen, Anders AU - Ganjoo, Kristen N AU - Yen, Chueh-Chuan AU - Abdul-Razak, Albiruni R AU - Spira, Alexander AU - Kawai, Akira AU - Le-Cesne, Axel AU - Van-Tine, Brian A AU - Naito, Yoichi AU - Park, Se Hoon AU - Fedenko, Alexander AU - Papai, Zsuzsanna AU - Soldatenkova, Victoria AU - Shahir, Ashwin AU - Mo, Gary AU - Wright, Jennifer AU - Jones, Robin L PY - 2020 DO - 10.1001/jama.2020.1707 UR - http://hdl.handle.net/10668/15335 T2 - JAMA AB - Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin... LA - en PB - American Medical Association KW - Antibiotics, Antineoplastic KW - Antibodies, Monoclonal KW - Doxorubicin KW - Drug Administration Schedule KW - Proportional Hazards Models KW - Young Adult KW - Adult KW - Aged KW - Aged, 80 and over KW - Antineoplastic Combined Chemotherapy Protocols KW - Double-Blind Method KW - Female KW - Humans KW - Male KW - Middle Aged KW - Placebos KW - Sarcoma KW - Survival Analysis TI - Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. TY - research article VL - 323 ER -